REGENERON PHARMACEUTICALS, INC. (REGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 1.99B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 7.99B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 41.73B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $1.99B | (m) | $7.99B | $41.73B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $1.99B | (m) | $8.75B | $40.87B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $1.99B | (m) | $8.61B | $40.56B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $1.99B | (m) | $8.44B | $40.17B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $1.99B | (m) | $7.47B | $38.22B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $1.98B | (m) | $8.35B | $37.55B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $1.98B | (m) | $9.01B | $37.76B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $1.98B | (m) | $9.80B | $37.44B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $1.98B | (m) | $9.81B | $36.09B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $1.98B | (m) | $10.52B | $34.37B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $1.98B | (m) | $10.84B | $33.08B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $1.98B | (m) | $9.91B | $32.16B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $1.98B | (m) | $8.93B | $30.66B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $1.98B | (m) | $8.96B | $30.06B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $1.98B | (m) | $7.74B | $29.21B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $1.98B | (m) | $7.02B | $27.68B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $1.98B | (m) | $7.57B | $27.21B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $1.98B | (m) | $7.05B | $26.35B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $1.98B | (m) | $5.69B | $25.43B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $1.98B | (m) | $5.79B | $23.67B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $1.98B | (m) | $3.91B | $21.49B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $1.98B | (m) | $3.50B | $17.77B | (m) |
| 2020-12-31 | (m) | (m) | (m) | $1.98B | (m) | $3.59B | $17.16B | (m) |
| 2020-09-30 | (m) | (m) | (m) | $1.98B | (m) | $3.03B | $16.08B | (m) |
| 2019-12-31 | (m) | (m) | (m) | $0.00 | (m) | $3.21B | $14.81B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |